Login Register Cart 0
Generic placeholder image

Current Diabetes Reviews

Editor-in-Chief

ISSN (Print): 1573-3998
ISSN (Online): 1875-6417

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Systematic Review Article

A Systematic Review on Pharmaceutical Diabetic Care Services in the United Arab Emirates (UAE)

Author(s): Syed Wasif Gillani*, Khanda Kareem Kaka Khan, Douaa Ladouani and Nour Alaa Salama

Volume 17, Issue 6, 2021

Published on: 28 December, 2020

Article ID: e122820189559 Pages: 7

DOI: 10.2174/1573399817999201228210029

Price: $65

Abstract

Objective: the aim of this systematic review study is to evaluate the current services and pharmaceutical care practices for diabetic patients in the UAE.

Methods: systematic review coverage conforms to the guidelines of the PRISMA; the search was limited to primary research articles, which describe the term “pharmaceutical diabetes care services in UAE”. The search strategy was developed in collaboration with a health database librarian, and a predetermined protocol was developed in conjunction with the authors for search methods.

Results: The findings showed the effect of a prescription treatment system on disease prevention and health-related quality of life in patients with type 2 diabetes in the United Arab Emirates. A retrospective interventional health evaluation was implemented to evaluate existing health procedures and the impact of conventional treatment on type 2 diabetes treatment (T2DM). The findings of this interventional evaluation were largely favorable, and the viability of changing the existing clinical procedure was stressed. The individualized strategy has helped clinicians finding a great result in terms of glycemic and BP, as well as patient satisfaction. The need for more work to clarify the long-term effect of organized strategy in enhancing the consistency of T2DM treatment in the UAE. The findings also showed increase community pharmacy services might further change the opinions of patients on the level of care provided by such pharmacies. The patients’ quality of life would improve by drug treatment efficacy and pharmacist services to mitigate diabetes complications.

The findings showed a prescription treatment system on disease prevention and health-related quality of life in patients with type 2 diabetes in the United Arab Emirates. A retrospective interventional health evaluation was implemented to evaluate existing health procedures and the impact of conventional treatment on type 2 diabetes treatment (T2DM). The findings of this interventional evaluation were largely favorable, and the viability of changing the existing clinical procedure was stressed. The individualized strategy has helped clinicians reach a great result in terms of glycemic and BP, as well as patient satisfaction. The need for more work to clarify the long-term effect of organized strategy in enhancing the consistency of T2DM treatment in the UAE. The findings also showed increase community pharmacy services mightfurther change the opinions of patients on the level of care provided by such pharmacies. The patients’ quality of life would improve by drug treatment efficacy and pharmacist services to mitigate diabetes complications.

Conclusion: This systematic review reported beneficial pharmacist-led diabetic management services in the UAE. Several care strategies were also highlighted to improve service for type 2 diabetes mellitus patients.

Keywords: Pharmacist, diabetes, care services, UAE, community pharmacy, pharmaceutical services, disease management, pharmacy services.

[1]
David HJ, Yosi W, Bruce S, Kreshnik H. The role of the pharmacist in the management of type 2 diabetes: current insights and future directions. Integr Pharm Res Pract 2017; 6: 15-27.
[http://dx.doi.org/10.2147/IPRP.S103783] [PMID: 29354547]
[2]
Meade LT, Tart RC, Buzby HL. Evaluation of diabetes education and pharmacist interventions in a rural. Primary care setting Diabetes Spectr 2018; 31(1): 90-5.
[http://dx.doi.org/10.2337/ds16-0064] [PMID: 29456431]
[3]
Jarab AS, Alqudah SG, Mukattash TL, Shattat G, Al-Qirim T. Randomized controlled trial of clinical pharmacy management of patients with type 2 diabetes in an outpatient diabetes clinic in Jordan. J Manag Care Pharm 2012; 18(7): 516-26.
[http://dx.doi.org/10.18553/jmcp.2012.18.7.516] [PMID: 22971205]
[4]
Khaled HN, Gillani SW, Abubakr KA, et al. A clinical review on nutritional requirements and assessment for type 2 diabetes mellitus with chronic renal disease. Curr Diabetes Rev 2020; 16: 01-9.
[5]
Doucette WR, Witry MJ, Farris KB, McDonough RP. Community pharmacist-provided extended diabetes care. Ann Pharmacother 2009; 43(5): 882-9.
[http://dx.doi.org/10.1345/aph.1L605] [PMID: 19401477]
[6]
Morello CM, Zadvorny EB, Cording MA, Suemoto RT, Skog J, Harari A. Development and clinical outcomes of pharmacist-managed diabetes care clinics. Am J Health Syst Pharm 2006; 63(14): 1325-31.
[http://dx.doi.org/10.2146/ajhp050430] [PMID: 16809752]
[7]
Armor BL, Britton ML, Dennis VC, Letassy NA. A review of pharmacist contributions to diabetes care in the United States. J Pharm Pract 2010; 23(3): 250-64.
[http://dx.doi.org/10.1177/0897190009336668] [PMID: 21507822]
[8]
Fazel MT, Bagalagel A, Lee JK, Martin JR, Slack MK, Marion K. Slack impact of diabetes care by pharmacists as part of health care team in ambulatory settings: a systematic review and meta-analysis. Ann Pharmacother 2017; 51(10): 890-907.
[http://dx.doi.org/10.1177/1060028017711454] [PMID: 28573873]
[9]
PRISMA http://www.prisma-statement.org/
[10]
Coeytaux RR, McDuffie J, Goode A, et al. Evidence Map of Yoga for High-Impact Conditions Affecting Veterans Washington (DC). US: Department of Veterans Affairs 2014.
[11]
Sadek MM, Elnour AA, Al Kalbani NM, et al. Community pharmacy and the extended community pharmacist practice roles: The UAE experiences. Saudi Pharm J 2016; 24(5): 563-70.
[http://dx.doi.org/10.1016/j.jsps.2015.03.023] [PMID: 27752229]
[12]
Hasan S, Sulieman H, Chapman C, Stewart K, Kong DCM. Community pharmacy in the United Arab Emirates: characteristics and workforce issues. Int J Pharm Pract 2011; 19(6): 392-9.
[http://dx.doi.org/10.1111/j.2042-7174.2011.00134.x] [PMID: 22060234]
[13]
Abduelkarem A, Sackville M. Changes of some health indicators in patients with type 2 diabetes: a prospective study in three community pharmacies in Sharjah. Libyan J Med 2009; 4(1): 31-6.
[http://dx.doi.org/10.3402/ljm.v4i1.4802] [PMID: 21483500]
[14]
Shehab A, Elnour A, Abdulle A. A clinical audit on diabetes care in patients with type 2 diabetes in Al-ain. United arab emirates. pen Cardiovasc Med J 2012; 6: 126-32.
[15]
Al Mazroui NR, Kamal MM, Ghabash NM, Yacout TA, Kole PL, McElnay JC. Influence of pharmaceutical care on health outcomes in patients with Type 2 diabetes mellitus. J Clin Pharmacol 2009; 67(5): 547-57.
[http://dx.doi.org/10.1111/j.1365-2125.2009.03391.x] [PMID: 19552750]
[16]
Bruchet N, Loewen P, de Lemos J. Improving the quality of clinical pharmacy services: a process to identify and capture high-value quality actions. Can J Hosp Pharm 2011; 64(1): 42-7.
[PMID: 22479028]
[17]
Rayes IK, Abrika OSS. In-patient and out-patient pharmacist intervention in the management of diabetes mellitus conditions in dubai. Res Pharm Health Sci 2017; 3: 303-7.
[18]
Akshar SAA, Shamssain DM, Metwaly PZ. Pharmacists perceptions of community pharmacy practice in UAE. An overview. IOSR J Pharm 2014; 4(11): 2319-4219.
[http://dx.doi.org/10.9790/3013-040601047056]
[19]
Dameh M. Pharmacy in the United arab emirates. South Med Rev 2009; 2(1): 15-8.
[PMID: 23093873]
[20]
Farah K, Amr KA, Alhomoud AF. Quality assessment of community pharmacy services provided in the united arab emirates: patientexperience and satisfaction. J Appl Pharm Sci 2016; 6(03): 2231-3354.
[21]
Kumar A, Bharti SK, Kumar A. Therapeutic molecules against type 2 diabetes: What we have and what are we expecting? Pharmacol Rep 2017; 69(5): 959-70.
[http://dx.doi.org/10.1016/j.pharep.2017.04.003] [PMID: 28822958]
[22]
Chen J-H, Ou H-T, Lin T-C, Lai E-C, Kao Y-H. Pharmaceutical care of elderly patients with poorly controlled type 2 diabetes mellitus: a randomized controlled trial. Int J Clin Pharm 2016; 38(1): 88-95.
[http://dx.doi.org/10.1007/s11096-015-0210-4] [PMID: 26499503]

Rights & Permissions Print Cite
Article Metrics
43
1
© 2024 Bentham Science Publishers | Privacy Policy